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Introduction: Interleukin-like epithelial-to-mesenchymal transition inducer (ILEI) is an essential cytokine in tumor
progression that is upregulated in several cancers, and its altered subcellular localization is a predictor of poor
survival in human breast cancer. However, the regulation of ILEI activity and the molecular meaning of its altered
localization remain elusive.
Methods: The influence of serum withdrawal, broad-specificity protease inhibitors, different serine proteases and
plasminogen depletion on the size and amount of the secreted ILEI protein was investigated by Western blot analysis
of EpRas cells. Proteases with ILEI-processing capacity were identified by carrying out an in vitro cleavage assay. Murine
mammary tumor and metastasis models of EpC40 and 4T1 cells overexpressing different mutant forms of ILEI were
used—extended with in vivo aprotinin treatment for the inhibition of ILEI-processing proteases—to test the in vivo
relevance of proteolytic cleavage. Stable knockdown of urokinase plasminogen activator receptor (uPAR) in EpRas cells
was performed to investigate the involvement of uPAR in ILEI secretion. The subcellular localization of the ILEI protein
in tumor cell lines was analyzed by immunofluorescence. Immunohistochemistry for ILEI localization and uPAR
expression was performed on two human breast cancer arrays, and ILEI and uPAR scores were correlated with the
metastasis-free survival of patients.
Results: We demonstrate that secreted ILEI requires site-specific proteolytic maturation into its short form for its
tumor-promoting function, which is executed by serine proteases, most efficiently by plasmin. Noncleaved ILEI is
tethered to fibronectin-containing fibers of the extracellular matrix through a propeptide-dependent interaction. In
addition to ILEI processing, plasmin rapidly increases ILEI secretion by mobilizing its intracellular protein pool in a
uPAR-dependent manner. Elevated ILEI secretion correlates with an altered subcellular localization of the protein,
most likely representing a shift into secretory vesicles. Moreover, altered subcellular ILEI localization strongly correlates
with high tumor cell–associated uPAR protein expression, as well as with poor survival, in human breast cancer.
Conclusions: Our findings point out extracellular serine proteases, in particular plasmin, and uPAR as valuable
therapeutic targets against ILEI-driven tumor progression and emphasize the prognostic relevance of ILEI localization
and a combined ILEI-uPAR marker analysis in human breast cancer.* Correspondence: agnes.csiszar@meduniwien.ac.at
ˆDeceased
1Research Institute of Molecular Pathology, Dr. Bohr-Gasse 7, A-1030 Vienna, Austria
7Current address: Institute of Cancer Research, Department of Medicine I,
Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria
Full list of author information is available at the end of the article
© 2014 Csiszar et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Csiszar et al. Breast Cancer Research 2014, 16:433 Page 2 of 18
http://breast-cancer-research.com/content/16/5/433Introduction
Metastasis of carcinomas is responsible for most cancer-
associated deaths [1], yet it is still the least understood
part of cancer pathogenesis. This illustrates the need for
a better understanding of the molecular mechanisms
driving tumor progression. The first permissive step of
metastasis is the physical dissemination of cancer cells
from the primary tumor, which is orchestrated by the
process of epithelial-to-mesenchymal transition (EMT)
[2]. Tumor cells in advanced primary carcinomas recruit a
variety of cell types into the surrounding stroma, which,
in response, release many EMT-inducing [1] and other
tumor-promoting signals [3,4]. Autocrine signaling loops
are later established by cancer cells to maintain EMT on
the voyage through different tissue environments [5,6].
Interleukin-like epithelial-to-mesenchymal transition
inducer (ILEI), also called FAM3C, is one of the secreted
factors that regulate tumor progression [7]. ILEI was found
in an expression profiling screen for transforming growth
factor β (TGFβ)-regulated EMT-specific genes [8]; it is
upregulated by TGFβ at the translational level [7,9,10].
Stable overexpression of ILEI in several murine tumor cell
lines induces EMT in vitro and elevated tumor growth
and metastasis in vivo [7,11]. Furthermore, RNA interfer-
ence (RNAi)-mediated knockdown (KD) of the protein
prevents or reverses TGFβ-dependent EMT and metasta-
sis formation [7,10]. Recombinant ILEI induces EMT
in vitro, suggesting that it is the secreted protein respon-
sible for ILEI function [7]. However, the failure to produce
bioactive recombinant ILEI in large quantities indicates
that crucial characteristics of its active form are still un-
known. Contrary to the originally described interleukin
(IL)-like fold [12], only a recent structural study shed light
onto ILEI/FAM3C and its family representing a new
structural class of noncytokine folds [13]. Importantly,
ILEI is overexpressed in several human tumors and shows
altered subcellular localization (granular to cytoplasmic),
which strongly correlates with metastasis formation and
survival in human breast and hepatocellular carcinomas
[7,11]. However, the molecular distinction between granu-
lar and cytoplasmic ILEI is still not understood.
Proteases have an important role during malignant
progression by acting as an extensive multidirectional
network of proteolytic interactions [14]. The plasmino-
gen (Plg)–Plg activator (PA) system is essential in extra-
cellular matrix (ECM) degradation, in the release and
activation of several growth factors, such as TGFβ1 [15]
and platelet-derived growth factors [16-18], as well as in
a number of cellular responses through the activation of
urokinase plasminogen activator receptor (uPAR) signaling
[19,20]. Plg can be converted into plasmin by the serine
proteases urokinase plasminogen activator (uPA) and tis-
sue plasminogen activator (tPA) [14]. Activation of uPA
is dependent on the binding of pro-uPA to its specificmembrane receptor uPAR and can be achieved by plasmin
itself, thus creating a feedback loop of reciprocal activation
[19]. Alternatively, kallikrein can activate both Plg [21] and
uPA [22]. Important negative regulators of the cascade are
plasminogen activator inhibitor 1 (PAI-1) and PAI-2 [23].
The cellular responses are mediated by direct contact of
uPAR with a variety of extracellular proteins and mem-
brane receptors, which results in the activation of diverse
intracellular signaling molecules [24]. Plasma kallikrein
also activates inflammation as part of the kallikrein–kinin
system [25]. Proteases of recruited inflammatory cells, such
as neutrophil elastase (NE), propagate angiogenesis and
invasiveness by ECM degradation and induction of tumor
cell proliferation [26]. In agreement with their role in can-
cer progression and metastasis, increased expression of
uPA, uPAR, PAI-1 and NE, and a positive correlation be-
tween their levels and a poor prognosis, have frequently
been reported in malignant tumors [26,27].
In this study, we show how proteases, in particular the
Plg-uPAR system, are involved at multiple levels in the
regulation of ILEI activity and the consequences of these
mechanisms on primary tumor growth and metastasis-
free survival, in both mouse and human models.
Methods
Cell culture
The EpRas and EpC40 cell lines, which are derivatives of
the immortalized murine mammary epithelial cell line
EpH4, were generated and characterized earlier in our
laboratory. EpRas is tumorigenic and metastatic because
of its transformation with oncogenic Ras (RasV12) [28],
whereas EpC40 is tumorigenic but not metastatic because
of the transformation with an effector-loop mutant
Ras oncogene (RasV12C40), which activates only the
phosphatidylinositol 3-kinase pathway [29,30]. EpRas and
EpC40 cells and their ILEI-overexpressing derivatives were
cultivated and recultivated from mouse tumors as de-
scribed previously [29,31]. Upon serum withdrawal, 10%
fetal calf serum (FCS) was replaced by 0.1% bovine serum
albumin. 4T1 cells were provided by Robert Weinberg
and were cultivated, including their RNAi-KD and ILEI-
overexpressing derivatives, as he and his colleagues pre-
viously described [31]. Human breast cancer cell lines
MCF7, T47D, MDA-MB-468, MDA-MB-231 and CAMA1
were donated by Gerhard Wirl and were cultivated as he
and his research group described elsewhere [32]. NIH3T3
cells were provided by Boehringer Ingelheim and were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% FCS.
Generation of stable cell lines expressing different ILEI
constructs and ILEI and uPAR shRNA vectors
Mouse ILEI coding sequence with a C-terminal 6xHis
affinity tag or FLAG epitope tag was PCR-cloned into
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containing point mutations and internal deletions were
generated using the in vitro Stratagene QuikChange
Site-Directed Mutagenesis kit (Agilent Technologies,
Santa Clara, CA, USA) with pcDNA3.1-ILEI-6xHis and
pcDNA3.1-ILEI-FLAG as templates. pcDNA3.1-ILEI-6xHis
constructs were recloned into the pMSCV-IRES-GFP
vector using EcoRI restriction sites, followed by the gener-
ation of stably transfected GP + E-86 retroviral producer
cell lines. Conditioned medium (CM) of the producers
was used to generate stable, retrovirally infected EpRas
cell lines overexpressing different ILEI-6xHis constructs.
The lentiviral expression vector pWPI (plasmid 12254;
Addgene, Cambridge, MA, USA) was used to generate
ILEI-FLAG constructs for stable mammalian gene expres-
sion. pWPI was modified by introducing a linker into the
PacI site of the vector, thereby extending the multiple
cloning site (MCS) with the unique BspEI, BamHI, SpeI
and SmaI restriction sites ( = pWPI-MCS). All ILEI-FLAG
constructs were recloned into the lentiviral expression
vector pWPI-MCS using the BamHI and SmaI restric-
tion sites. Lentiviral transducing particles were produced
by transient cotransfection of the pWPI-ILEI-FLAG
constructs together with the packaging and envelope
vectors psPAX2 and pMD2.G (plasmids 12260 and
12259; Addgene) [33] into 293FT cells. Forty-eight hours
after transfection, CM containing the virus particles was
taken to infect EpC40 and EpRas cells and RNAi-KD
derivatives of the 4T1 cell line.
Sequence fidelity and the presence of the desired
mutations were confirmed by DNA sequence analysis.
All infected cells were sorted twice by fluorescence-
activated cell sorting for stable green fluorescent protein
expression. ILEI expression levels were analyzed on West-
ern blots using anti-ILEI, anti-penta-His and anti-FLAG
antibodies.
For KD of ILEI in 4T1 and uPAR in EpRas cells,
MISSION short-hairpin RNA (shRNA) lentiviral trans-
duction particles (Sigma-Aldrich, St Louis, MO, USA)
were used according to the manufacturer’s instructions.
Transduced cells were selected for puromycin resistance.
ILEI expression was studied by Western blot analysis and
uPAR expression was assessed by qRT-PCR using glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) expression
for normalization as well as primers from QIAGEN
(Hilden, Germany).
Protease inhibitor studies on ILEI cleavage
EpRas cells were treated for 24 hours with the follow-
ing inhibitors: 100 μM E64, 100 μM CA-074, 10 μM
pepstatin A, 100 μM GM6001, 500 μM (4-(2-aminoethyl)-
benzolsulfonylfluorid-hydrochloride) (AEBSF; Merck,
Darmstadt, Germany) and 10 μM aprotinin (Lactan,
Graz, Austria).Protein purification and immunoprecipitation
Different forms of ILEI-6xHis or ILEI-FLAG were affinity-
purified using nickel-nitrilotriacetic acid (Ni-NTA) super-
flow resins (QIAGEN) or were immunoprecipitated using
anti-FLAG M2 agarose (Sigma-Aldrich) from whole-cell
lysates and CM of overexpressing EpRas cells. 6xHis affin-
ity purification was performed under native conditions
according to the manufacturer’s instructions using 5 mM,
20 mM and 150 mM imidazole (pH 8.0) in the capturing,
washing and elution buffers, respectively. For FLAG
immunoprecipitation, cells were lysed in phospholipase
C (PLC) buffer (10% (vol/vol) glycerol, 50 mM 2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (pH 7.5),
150 mM NaCl, 0.5% (vol/vol) Triton X-100, 1.5 mM
MgCl2, 1 mM ethylene glycol tetraacetic acid, 200 μM
Na3VO4 and 10 mM NaF supplemented with cOmplete
Protease Inhibitor Cocktail tablets (Roche Diagnostics,
Basel, Switzerland), and lysates or CM of these cells were
incubated overnight with FLAG beads. Beads were washed
in PLC buffer and directly boiled in 2× SDS-PAGE loading
buffer for analytical coimmunoprecipitation studies or
washed an additional three times in detergent-free PLC
buffer, once in 150 mM NaCl, and then eluted with 0.1 M
glycine (pH 2.0). Eluates were neutralized with 1.5 M
Tris-HCl (pH 9.2) and used for mass spectroscopy or
in vitro assays. During purification of ILEI proteins,
which were used as a substrate for in vitro cleavage assays,
all washing and elution steps were performed in the ab-
sence of cOmplete Protease Inhibitor Cocktail.
In vitro ILEI cleavage assay
Purified, full-length ILEI-FLAG or ILEI-6xHis proteins
were incubated with proteases (250 U of human uPA, 50
U of human tPA, 0.5 to 2.5 U of bovine thrombin, 2.5 to
12.5 mU of human plasma kallikrein and 50 μU to 5 mU
of NE (Merck) and 25 μU to 5 mU of bovine plasmin
(Roche Diagnostics)) at 37°C for 5 hours, followed by
Western blot analysis. Equal amounts of purified, full-
length ILEI-6xHis were incubated with 1 ml of serum-free
medium or medium containing 10% FCS. ILEI protein
was repurified from the 1-ml solutions under equal condi-
tions via its 6xHis affinity tag using Ni-NTA spin columns
(QIAGEN) according to the manufacturer’s instructions,
and equal loads of eluates were analyzed on Western blots
using ILEI antibody.
ILEI secretion assay
Serum-free medium was added after cell adherence with
or without the proteases listed above. For the time-
course analysis, 10 ng/ml TGFβ-1 (PeproTech, Rocky
Hill, NJ, USA) and 5 mU of plasmin were added to the
cells directly at 12, 16, 20, 22, 23 and 23.5 hours after
serum withdrawal. Aprotinin treatment (10 μM) of wild-
type EpC40 (EpC40-wt) was performed for 32 hours
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harvested 24 hours after the last media change, and ILEI
levels were determined by Western blot analysis.
Western blot analysis
CM were concentrated via ultrafiltration using mini spin
filter columns MWCO 10 kDa (Merck). Cells were har-
vested, and total cell numbers were determined. Gel load-
ing of CM was normalized to the concentrated volume
and total cell numbers. Loading of cell lysates was normal-
ized to the total protein content (Bradford assay; Bio-Rad
Laboratories, Hercules, CA, USA). Western blot analysis
was performed using anti-ILEI [7], anti-FLAG M2 and
anti-β actin antibodies (Sigma-Aldrich). Quantification of
Western blots was performed using ImageJ software (Na-
tional Institutes of Health, Bethesda, MD, USA).
Plasminogen depletion of fetal calf serum
Lysine Sepharose 4B affinity medium (GE Healthcare,
Chalfont St Giles, UK) was prepared, packed into columns
and equilibrated with phosphate-buffered saline (pH 7.2)
according to the manufacturer’s instructions. FCS was
applied to the column, and flow-through was reapplied
onto fresh columns an additional two times. Final flow-
through was tested for residual plasmin activity using the
synthetic chromogenic plasmin substrate D-Val-Leu-Lys-
pNA (S-2251™; Chromogenix, Lexington, MA, USA).
ILEI cleavage assay with blood plasma of
plasminogen-knockout mice
Blood plasma of C57BL/6 Plg-KO mice (The Jackson
Laboratory, Bar Harbor, ME, USA) and of their hetero-
zygous and WT littermates was prepared by collecting
peripheral blood into MiniCollect tubes (K3EDTA; Greiner
Bio-One, Kremsmünster, Austria) and collecting the
cell-free supernatant after centrifugation. Purified, WT,
full-length ILEI-FLAG was incubated with 10% plasma
of mice of the above-mentioned genotypes at 37°C for
5 hours, followed by ILEI Western blot analysis.
ILEI binding assay to fibroblast-deposited extracellular
matrix
Cell-free ECM deposited by NIH 3T3 fibroblasts was
prepared as described elsewhere [34], incubated with
different purified ILEI proteins and fixed after rigorous
washing. Immunofluorescent staining was performed using
fibronectin (Sigma-Aldrich) and penta-His (QIAGEN)
antibodies.
Determination of relative gene expression levels in tumor
cell lines
Total RNA of MCF7, T47D, MDA-MB-468, MDA-MB-231
and CAMA1, as well as EpRas cells and its derivatives, was
isolated using TRIzol reagent (Invitrogen, Carlsbad, CA,USA), and cDNA was synthesized using SuperScript II
Reverse Transcriptase (Invitrogen) according to the manu-
facturer’s instructions. Quantitative RT-PCR was perfor-
med using the SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA, USA) and primers from
QIAGEN and from the qPrimerDepot [35]. Expression
levels of uPAR, uPA, tPA, PAI-1 and PAI-2 were normal-
ized to GAPDH expression.
ILEI colocalization studies
EpC40-wt cells with or without plasmin and aprotinin
treatments, EpC40-ΔN-RS and EpC40-FD cells were fixed
and immunostained with FLAG M2 (Sigma-Aldrich),
GM130 (BD Biosciences, Franklin Lakes, NJ, USA), ILEI
[7], early endosome antigen 1 (EEA1; BD Biosciences),
giantin (Abcam, Cambridge, UK), lysosomal-associated
membrane protein 1 (Lamp1, 1D4B; Developmental
Studies Hybridoma Bank, Iowa City, IA, USA), TGN38
(Novus Biologicals, Littleton, CO, USA) and primary
and Alexa Fluor 568 and Alexa Fluor 647 fluorochrome-
coupled secondary antibodies (Invitrogen). Hoechst
33258 (Invitrogen) was used for DNA counterstaining.
For transferrin uptake studies, cells were serum-starved
for 4 to 6 hours, incubated with growth medium sup-
plemented with transferrin-Alexa Fluor 568 (Invitrogen)
for 45 minutes and fixed, followed by ILEI immunostain-
ing. For transient expression of mCherry-Rab8a protein,
cells were transfected with pCherry-C1-Rab8a plasmid
using Lipofectamine LTX reagent (Invitrogen) according
to the manufacturer’s instructions, cultivated for another
24 hours and fixed followed by ILEI immunostaining.
Cells were fixed and permeabilized with 4% formalde-
hyde/0.1% Triton X-100 or with methanol:acetone (1:1)
(for TGN38 staining). Immunofluorescence was detected
by confocal microscopy (LSM 510/Axiovert 200 M (Zeiss,
Oberkochen, Germany) and Leica SP5 (Leica Microsys-
tems, Wetzlar, Germany)).
FLAG immunohistochemistry on paraformaldehyde-
fixed, paraffin-embedded, 3-μm-thick sections of mouse
tumor tissues was performed using the staining unit
Discovery (Ventana Medical Systems, Tucson, AZ, USA).
Experimental tumor and metastasis assays
Animal work was done by following earlier protocols
that received ethical approval from the Institutional
Animal Care and Use Committee of the Research In-
stitute of Molecular Pathology and from the Austrian
Bundesministerium für Bildung, Wissenschaft und Kultur.
Tumor formation and metastatic ability of derivatives of
EpC40 and 4T1 cells were determined by mammary gland
fat pad and tail vein injections into 8- to 12-week-old
NMRI athymic nude female mice (Charles River Wiga
GmbH, Sulzfeld, Germany) as described previously
[29,31]. Each experimental group contained five to ten
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were injected and tumor growth was monitored by
weekly measurement of the tumor diameter. Tumor
volume was calculated by the formula a × b2/2, with a
representing the major and b the minor tumor diameter.
For metastasis assays, 2 × 105 recultivated, EpC40-derived
tumor cells were injected into the tail vein. Aprotinin
treatment of mice was carried out by a daily intraperito-
neal injection of 4,000 kallikrein inactivator units (KIU) of
aprotinin (Lactan) dissolved in 100 μl of sterile, filtered
0.9% NaCl for the entire period of the experiment.
Quantification of lung metastasis was performed by cal-
culating the percentage of metastatic lung area. Each lung
was cut through serially in 3-μm-thick sections at 300-μm
intervals, sections were stained with hematoxylin and
eosin and scanned (Mirax scanner; Zeiss). The absolute
value of metastatic and total lung area of each section was
determined using an algorithm developed in and executed
using the Definiens software suite (Definiens, Munich,
Germany), and the percentage of metastatic lung area per
mouse was calculated from the sum of metastatic and
total lung areas of all sections of the lung.
Metastasis analysis of derivatives of 4T1 cells was per-
formed by injection of 5 × 105 cells into the fifth pair of
mammary gland fat pads. Mice were killed 30 days after
injection, and primary tumors and lung metastases were
analyzed as described above.
Human breast cancer tissue array
All human tissue material was collected from patients who
had undergone surgery at the Medical University of Vienna
and was analyzed under protocol 141/2002 approved by
the Institutional Review Board (IRB, “Ethikkommission”)
of the Medical University of Vienna. Specific informed
consent to participate in the study and to use samples and
records was obtained from patients recruited after the
onset of the study. For patients who underwent surgery
before the start of the study, the IRB approved a waiver of
specific informed consent. Two tissue arrays from 108 fe-
male breast cancer patients were analyzed retrospectively
[7,36]. They were processed manually for immunohis-
tochemistry (IHC) using ILEI and uPAR (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) antibodies, and
immunostained arrays were scanned in the Mirax scanner.
Subcellular ILEI localization was scored as described else-
where [7]. For tumor cell–associated uPAR expression a
semiquantitative intensity score was used on a scale of 0
to 5 (0, no immunoreactivity; 1, very weak; 2, weak; 3
moderate; 4 strong; 5 very strong). No intensity and weak
staining intensity (scores 0 to 2) were considered low
uPAR expression, and moderate and strong staining inten-
sities (scores >2) were considered high uPAR expression.
This uPAR cutoff was validated with a receiver operating
characteristic curve. ILEI scoring was performed by threeindependent observers and uPAR by two. For technical
reasons, the ILEI IHC score was not evaluable for 12
patients, the uPAR score for 2 patients and both markers
for 6 patients. Accordingly, all further analyses were based
on 88 patients.
Statistical analysis
Data are expressed as the mean ± SEM where applicable.
Statistical significance was determined by unpaired, two-
sided Student’s t-test. P < 0.05 was considered significant,
and these values are marked with asterisks (*P < 0.05;
**P < 0.01). Kaplan-Meier plots were computed with the
survival package of R statistical software (The R Project
for Statistical Computing, Vienna, Austria). Corresponding
P-values were calculated as described elsewhere [37]. Cor-
relations of ILEI and uPAR IHC status with clinical and
histopathological parameters were evaluated with Fisher’s
exact test.
Results
ILEI is processed extracellularly by the serine proteases
plasmin, plasma kallikrein and neutrophil elastase
Mass spectrometric analysis has shown that, in addition
to the signal peptide, secreted ILEI lacks 17 amino acids
(propeptide) at the N terminus, indicating a proteolytic
processing of the protein [7]. Western blot analysis of
whole-cell extracts and CM of EpRas cells, grown under
normal and serum-free conditions, indicated that cleavage
might occur in the extracellular space and pointed to an
involvement of the serum in ILEI processing (Figure 1A).
Importantly, purified ILEI was also cleaved by medium
supplemented with 10% FCS (Figure 1B), albeit to a mod-
est extent in comparison to the endogenously secreted
protein. Neither secreted nor membrane-tethered compo-
nents significantly increased the moderate ILEI-processing
capacity of FCS in purified material (Additional file 1:
Figure S1A), indicating that it might be a consequence
of either the purification procedure or the influence of
spatial arrangement of extracellular ILEI on cleavage.
Solely inhibitors of serine proteases—aprotinin and, to a
weaker extent, AEBSF—were capable of inhibiting ILEI
cleavage in the CM of EpRas cells (Figure 1C), indicat-
ing that serine-type serum proteases are involved in
ILEI processing.
To identify the ILEI-processing protease, we perfor-
med in vitro cleavage assays with candidate proteases.
On the basis of their important role in cancer progres-
sion and in the processing of growth factors, we selected
plasmin, tPA, uPA and NE [26,38,39]. However, we knew
that cleavage should occur between arginine and serine
residues. Thus, we also focused also on proteases known
to have this consensus cleavage recognition site. These
proteases were studied in addition to plasmin, thrombin
and plasma kallikrein. Whereas tPA and uPA showed no
Figure 1 Interleukin-like epithelial-to-mesenchymal transition inducer is processed extracellularly by serine proteases, most efficiently
by plasmin. (A) Western blot analysis of interleukin-like epithelial-to-mesenchymal transition inducer (ILEI) in whole-cell lysate and conditioned
medium (CM) of EpRas cells grown in 10% fetal calf serum (FCS) or under serum-free conditions. Loading was not normalized to cell numbers.
Full-length ILEI runs at the size of 26 kDa, the processed form approximately 2 kDA lower. (B) Purified full-length ILEI-6xHis was incubated with
serum-free Dulbecco’s modified Eagle’s medium (DMEM) or medium containing 10% FCS (DMEM 10%) for 5 hours. ILEI protein was repurified via
its 6xHis affinity tag and subjected to Western blot analysis. (C) Western blot analysis of ILEI in CM of EpRas cells cultured in the presence of the
broad-specificity inhibitors against cysteine proteases (E64), cathepsin B (CA-074), matrix metalloproteases (GM6001) and serine-type proteases
(4-(2-aminoethyl)-benzolsulfonylfluorid-hydrochloride (AEBSF) and aprotinin) for 24 hours. (D) to (F) Purified intracellular, full-length ILEI-6xHis was
subjected to Western blot analysis after incubation for 2 to 5 hours with the indicated amounts of purified (D) plasmin, uPA and tPA; (E) plasmin,
thrombin and plasma kallikrein; and (F) plasmin, thrombin and neutrophil elastase (NE).
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Thrombin, plasma kallikrein and NE were also able to
process purified, full-length ILEI (Figure 1E and F). None
of the enzymes acted on the short, processed form of the
protein (data not shown), indicating that all of them
recognized a cleavage site that led to the removal of the
propeptide. Considering the very different amounts of
these four proteases required for ILEI-processing plasmin,
plasma kallikrein and NE were physiologically relevant
candidates for ILEI cleavage.
To test the prevalent role of plasmin in ILEI processing,
we analyzed ILEI in the CM of EpRas cells upon cultiva-
tion in Plg-depleted FCS. Plg depletion did not completely
eliminate ILEI cleavage (Additional file 1: Figure S1B). In a
further test, an ILEI cleavage assay was performed with
blood plasma of Plg-KO mice. Similarly, lack of plasmin in
the plasma only partially reduced the accumulation of
processed ILEI (Additional file 1: Figure S1C), suggesting
that other serine-type proteases, most probably NE and
kallikrein, also act on ILEI at physiological concentrations.Identification of a physiological proteolytic cleavage site
in ILEI
To validate the recognition site for proteolytic cleavage,
mutations were introduced at the mapped N-terminal
start of secreted ILEI generating the constructs FD and DF
(cleavage mutants, Figure 2A). We also generated the ILEI
constructs ΔN-RS and ΔN-LD lacking the propeptide
sequence (Δ-propeptide mutants, Figure 2A). A lentiviral
vector was used to introduce C-terminal, FLAG-tagged
versions of these constructs and to generate stably infec-
ted EpC40 cells. The cleavage-mutant ILEI forms FD and
DF were not cleaved by plasmin in vitro (Additional file 1:
Figure S1D), showing that the mapped arginine-serine site
is the cleavage recognition site.
Western blot analysis of whole-cell extracts verified
that both cleavage-mutant and both Δ-propeptide-mutant
forms of ILEI were efficiently expressed and secreted in
EpC40 cells at their expected sizes, albeit to somewhat
different levels (Figure 2B). Nevertheless, a weak band at
the size of processed ILEI was observed in the CM of
Figure 2 (See legend on next page.)
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Figure 2 Removal of the propeptide is required for elevated tumor growth and lung colonization of EpC40 cells. (A) Schematic drawing
of the interleukin-like epithelial-to-mesenchymal transition inducer (ILEI) protein and ILEI constructs used in this study. wt, Wild type. (B) ILEI and
FLAG Western blot analysis of whole-cell lysates and conditioned medium (CM) of EpC40 cells overexpressing the ILEI constructs listed in (A). (C)
and (D) Primary tumor growth capacity of EpC40 cells overexpressing empty vector or different ILEI forms was determined upon injection into
the mammary gland fat pads of female nude mice (n = 5 per group). (C) Tumor growth rate by calculated tumor volume 41 days after injection
(±SEM). (D) Tumor mass 41 days after injection (±SEM). (E) and (F) Lung colonization capacity of EpC40 cells overexpressing empty vector or
different ILEI forms was determined upon intravenous injection of recultivated cells of mammary tumors into female nude mice (n = 5 per group).
Lungs were dissected and analyzed for metastases 45 days after injection. (E) Hematoxylin and eosin–stained histological sections of representative
lungs of each group. Scale bar, 2 mm. (F) The percentage of lung metastatic area of each group (±SEM).
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enzymes would still recognize the altered protein se-
quence. We rather would think that a second arginine-
serine site, only six amino acids further toward the C
terminus of the protein, might be recognized in these
mutants. However, our mass spectrometric data indicate
that the second cleavage site was not used under physio-
logical conditions.
Removal of ILEI propeptide is essential for ILEI-dependent
increase in tumor growth and metastasis induction
To study the role of ILEI cleavage in tumor develop-
ment, we tested the activity of the different ILEI mutants
in tumor formation and metastasis assays. Mammary
gland fat pad injections were performed with EpC40
cells overexpressing WT and mutant forms of the pro-
tein. As described elsewhere [7] and in Figure 2C and D,
ILEI-wt-overexpressing EpC40 cells show significantly
elevated tumor growth. Cleavage-mutant (FD) ILEI-over-
expressing cells had low tumor growth capacity, similar
to control cells (Figure 2C and D). Interestingly, the two
Δ-propeptide ILEI forms (ΔN-RS and ΔN-LD) accelerated
tumor growth of EpC40 cells even more than ILEI-wt did
(Figure 2C and D). These data show that a noncleavable
ILEI form had no activity, indicating that cleavage plays an
important role in the activation of the protein. In addition,
the moderate tumor growth capacity of ILEI-wt- compared
to Δ-propeptide ILEI–overexpressing cells suggests that the
mere availability of ILEI-processing proteases in the tumor
microenvironment might be a regulatory factor of active
ILEI levels.
Because EpC40 cells are not able to metastasize
from primary tumor sites, recultivated cells of the
above-described EpC40 tumors were injected intra-
venously into mice to model late aspects of metasta-
sis. ILEI-wt- and Δ-propeptide ILEI–overexpressing
tumor cells formed large lung metastases in all ani-
mals, as expected ([7] and Figure 2E and F). In con-
trast to primary tumor formation ability, the difference in
the metastatic capacity between these cells was not signifi-
cant. Cleavage-mutant, ILEI-overexpressing tumor cells
showed only some weak capacity to induce small metasta-
ses (Figure 2E and F).We tested the general necessity of proteolytic processing
for ILEI function by analyzing the activity of the different
ILEI forms in metastatic 4T1 murine mammary cancer
cells that expressed and secreted high levels of ILEI, too
(Additional file 2: Figure S2A). Whereas EMT/metastasis
promoter and suppressor genes also influence primary
tumor growth in EpC40 cells [5,7,40], they act exclusively
on the metastatic capacity of 4T1 cells from the orthoto-
pic site [31,41,42]. Consistent with this, stable RNAi-KD
of ILEI solely decreased lung metastasis of 4T1 cells
(Additional file 2: Figures S2B to S2D). The metastatic
behavior of the different ILEI forms was tested by re-
constituting 4T1 ILEI-KD cells with the above-described
ILEI constructs (Additional file 2: Figure S2A). Import-
antly, reexpression of WT and Δ-propeptide (ΔN-RS) ILEI
turned these cells highly metastatic again in a comparable
manner, whereas cleavage mutant (FD) ILEI showed only
weak metastasis-promoting activity (Additional file 2:
Figures S2C and S2D). None of the reexpressed ILEI forms
had a significant effect on primary tumor size (Additional
file 2: Figure S2B). In summary, the metastatic capacity
of 4T1 ILEI-KD cells reconstituted with different mutant
ILEI forms was reminiscent of the lung colonization activ-
ity of these proteins upon overexpression in EpC40 cells,
indicating that our observations in EpC40 cells may have
general validity, in breast cancer cells at least.
Inhibition of ILEI processing interferes with elevated
tumor growth and metastasis induction
To investigate the necessity of ILEI processing for both
increased tumor growth and metastasis formation, we
retested the tumorigenic and lung colonization ability
of EpC40 cells overexpressing different ILEI forms in
aprotinin-treated mice. Importantly, the ILEI-induced
increase in tumor growth was suppressed by aprotinin
treatment of ILEI-wt-overexpressing cells, but not Δ-
propeptide ILEI–overexpressing cells (Figure 3A and B),
indicating that serine protease activity was essential to
generate the processed functional form of ILEI in vivo.
Aprotinin is known to accelerate metastasis formation
due to its effect on blood clotting [43]. Accordingly, all
tumor cell lines showed a certain capacity in the lung
colonization assay to induce metastasis-driven terminal
Figure 3 Aprotinin suppresses increased tumor growth and lung colonization of wild-type interleukin-like epithelial-to-mesenchymal
transition inducer–overexpressing EpC40 cells. Analysis of primary tumor growth and lung colonization capacity of EpC40 cells and
derivatives in aprotinin (Ap)-treated mice was performed as described in the Figure 2 legend (n = 10 per group). Five mice in each group were
administered with 4,000 kallikrein inactivator units of aprotinin daily. Error bars show mean ± SEM. (A) Tumor growth rate. (B) Tumor masses.
(C) Lung colonization assay. Moribund mice were killed and analyzed for lung metastases. The experiment was terminated 80 days after tumor
cell injection. The frequency of survival is represented in two separate Kaplan-Meier plots, with the upper showing untreated mice and the lower
aprotinin-treated mice.
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ent kinetics. Aprotinin accelerated the onset of terminal
sickness of mice injected with Δ-propeptide (ΔN-RS) ILEI-
overexpressing cells by about 2 weeks and moderately
decreased survival of mice injected with cleavage-
mutant (FD) ILEI-overexpressing or control EpC40 cells
(Figure 3C). Most importantly, however, ILEI-wt-over-
expressing tumor cells showed a significant decrease in
metastatic capacity in aprotinin-treated mice (Figure 3C).
These data show that aprotinin decreased metastatic cap-
acity only in cells that were sensitive for ILEI processing,
indicating that proteolytic processing of ILEI is also essen-
tial for metastasis formation. Hence, the differences in the
activity of the different ILEI forms in tumorigenesis and
metastasis assays are most likely a consequence of saturat-
ing ILEI-processing protease activity in blood and lungcompared to tumor tissue. Because cleavage-mutant
ILEI was still a weak substrate for processing, its residual
metastatic capacity might also be explainable by high local
protease concentrations.
Propeptide tethers ILEI to fibronectin-containing
extracellular matrix complexes
To investigate the molecular role of ILEI processing, we
aimed to find interactors specifically binding processed
or nonprocessed ILEI. For this purpose, FLAG immu-
noprecipitates of WT and cleavage-mutant (FD) ILEI
from CM of overexpressing EpRas cells were analyzed
by mass spectrometry. We identified fibronectin in
the precipitate of cleavage-mutant ILEI (FD), but not
ILEI-wt. This interaction was confirmed in coimmunopre-
cipitation experiments using the same conditions as we
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coprecipitated only with cleavage-mutant (FD) ILEI
(Figure 4A), suggesting that ILEI interacts with soluble
fibronectin in a propeptide-dependent manner.
Fibronectin is a component of the ECM. This prompted
us to test whether ILEI would be able to bind to the ECM
in a propeptide-dependent manner. Purified, processed
WT and cleavage-mutant (FD) 6xHis-tagged ILEI were
incubated with prepared cell-free ECM deposited by
NIH 3T3 fibroblasts. Only cleavage-mutant (FD), and
not processed, ILEI-wt accumulated along deposited
fibers of the ECM, which we visualized by using a
fibronectin-specific antibody (Figure 4B). These data are
consistent with our immunoprecipitation results and
support the idea that the ILEI propeptide plays an import-
ant role in tethering the protein to the ECM by direct or
indirect interaction with fibronectin and that release may
occur by proteolytic cleavage.Figure 4 Interleukin-like epithelial-to-mesenchymal transition inducer bi
matrix complexes via its propeptide. (A) Western blot analysis of wild-type
transition inducer (ILEI) immunoprecipitated (IP) from conditioned medium of
extracellular soluble fibronectin was probed using a fibronectin-specific antibod
(FD) ILEI-6xHis proteins after incubation with prepared cell-free extracellular ma
visualized via the 6xHis affinity tag using penta-His antibody (green). ECM was
fraction of empty vector expressing EpRas cells was used as control. Scale bar,Plasmin induces ILEI secretion by rapidly mobilizing its
intracellular protein pool
We confirmed that plasmin was sufficient to process
secreted ILEI in EpRas cell culture. More strikingly,
however, a dramatic increase in ILEI secretion of these
cells was observed upon plasmin treatment, combined
with a decrease in the intracellular levels of the protein
(Figure 5A). We tested the dose dependency of plasmin
on these effects (Additional file 3: Figure S3A). The lowest
amount of plasmin was already able to fully stimulate ILEI
secretion, whereas nonprocessed ILEI disappeared only
with increasing concentrations of plasmin, suggesting that
secreted ILEI might primarily accumulate in its uncleaved,
inactive form at limiting concentrations of plasmin.
Plasmin appeared to be even more potent in increasing
ILEI secretion than TGFβ (Additional file 3: Figure S3B).
ILEI secretion reached maximal levels as soon as 1 hour
after addition of plasmin, combined with a significantnds to soluble and deposited fibronectin-containing extracellular
(wt) or cleavage mutant (FD) interleukin-like epithelial-to-mesenchymal
overexpressing EpRas cells via their FLAG epitope tags. Coprecipitation of
y. (B) Immunofluorescence analysis of purified WT and cleavage mutant
trix (ECM) deposited by NIH 3T3 fibroblasts. Bound ILEI proteins were
counterstained with a fibronectin-specific antibody (red). The purification
5 μm.
Figure 5 Plasminogen-urokinase plasminogen activator receptor signaling rapidly upregulates interleukin-like epithelial-to-mesenchymal
transition inducer secretion by mobilizing its intracellular protein pool. (A) to (D) Western blot analysis of interleukin-like epithelial-to-
mesenchymal transition inducer (ILEI) in whole-cell lysates and conditioned medium (CM) of EpRas cells not treated or treated with plasmin for
16 hours after serum withdrawal (A), harvested 24 hours after serum withdrawal and incubation with plasmin for the indicated periods of time (B),
treated with indicated concentrations of plasmin, thrombin or plasma kallikrein for 24 hours after serum withdrawal (C) and treated with indicated
concentrations of neutrophil elastase (NE) for 24 hours after serum withdrawal (D). (E) Fold change ± SEM in ILEI secretion of EpRas cells after plasmin,
thrombin, plasma kallikrein and NE treatments calculated by semiquantification of Western blots of three independent experiments. (F) and (G) Western
blot analysis of ILEI in whole-cell lysates and CM of EpRas cells treated with indicated concentrations of plasmin, tissue plasminogen activator (tPA) or
urokinase plasminogen activator (uPA) for 24 hours after serum withdrawal (F) and in control and urokinase plasminogen activator receptor (uPAR)
short-hairpin RNA EpRas cells not treated or treated with plasmin or transforming growth factor β-1 (TGFβ-1) for 24 hours after serum withdrawal (G).
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In contrast, TGFβ upregulated intracellular ILEI within 4
to 8 hours via its effect on translation [7,10]; however,
secretion levels increased only after 8 hours (Additional
file 3: Figure S3C). In summary, plasmin, unlike TGFβ,
rapidly stimulated ILEI secretion at the expense of the
intracellular ILEI protein pool.
Plasminogen–urokinase plasminogen activator receptor
signaling regulates ILEI secretion
To discover whether the effect of plasmin on ILEI secre-
tion depended on ILEI cleavage, we tested the capability of
the other ILEI-processing proteases—thrombin, kallikrein
and NE—to enhance secretion of the protein. In contrast
to plasmin, they neither increased secreted intracellularILEI levels nor decreased them in EpRas cells (Figure 5C
to E), suggesting that plasmin might induce secretion
independently of ILEI cleavage.
We therefore focused on the potential role of uPAR
signaling in ILEI secretion. We tested whether direct ac-
tivation of uPAR could induce ILEI secretion. Incubation
of EpRas cells with active uPA induced ILEI secretion in
a dose-dependent manner, and it was coupled with a
decrease in intracellular ILEI levels (Figure 5F and
Additional file 3: Figure S3D). To show directly that uPAR
is essential in the regulation of ILEI secretion, we generated
stable uPAR-KD EpRas cells and tested them for their
capability to induce ILEI secretion upon plasmin treat-
ment. EpRas sh_uPAR-1 cells showed efficient depletion
(approximately 80%; see Additional file 3: Figure S3E), and
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expression (about 50%; see Additional file 3: Figure S3E).
Importantly, plasmin-induced ILEI secretion was signi-
ficantly impaired in these cells and correlated with their
residual amount of uPAR in a dose-dependent manner
(Figure 5G), indicating that uPAR is required in this
process. In accordance with this finding, intracellular ILEI
levels of these cells either were not or were only moder-
ately decreased (Figure 5G). Depending on the culture
conditions, EpRas cells with partial uPAR KD (EpRas-
sh_uPAR-2) showed differences in their sensitivity to
plasmin-induced ILEI secretion (data not shown). Inter-
estingly, uPAR KD not only interfered with plasmin-
induced ILEI secretion but also inhibited TGFβ-induced
secretion (Figure 5G), indicating that uPAR might be a
more general regulator of ILEI secretion by integrating
several signals. In summary, these results strongly support
the hypothesis that plasmin-induced upregulation of ILEI
secretion is independent of its activity on ILEI cleavage
and acts most probably via uPAR signaling. In addition, al-
though TGFβ- and plasmin-induced ILEI secretion could
be uncoupled at the level of the translational control of
ILEI, they might share the same uPAR-dependent regula-
tory mechanism of secretion.
We also analyzed the uPAR-dependent regulation of
ILEI secretion in a series of human breast cancer cell
lines. Whereas nonmetastatic cell lines (T47D and MCF7)
expressed and secreted low levels of ILEI and did not
express uPAR, uPA, tPA PAI-1 or PAI-2, metastatic cell
lines (MDA-MB-468, MDA-MB-231 and CAMA1) ex-
pressed and secreted high ILEI levels and expressed uPAR
and partially expressed additional components (Additional
file 4: Figures S4A and S4B). Furthermore, plasmin treat-
ment of MCF7 and MDA-MB-231 cells induced increased
ILEI secretion only in uPAR-expressing MDA-MB-231
cells (Additional file 4: Figure S4C). In summary, the
extent and inducibility of ILEI secretion correlated with
the expression levels of uPAR in these cells, indicating that
the necessity of uPAR signaling for ILEI secretion might
also be relevant in humans.
ILEI secretion levels correlate with altered subcellular
localization of the protein
Altered subcellular localization of ILEI correlates with
metastasis-free survival in breast cancer, and ILEI secre-
tion correlates with the metastatic capacity of several
cancer cell lines [7]. This prompted us to investigate
whether differences in ILEI secretion levels would be
reflected in an altered subcellular localization of the pro-
tein. For this purpose, we induced elevated or decreased
ILEI secretion in ILEI-wt-overexpressing EpC40 cells by
plasmin or aprotinin treatment (Figure 6A) and analyzed
the subcellular localization of the protein. Normally,
ILEI localized to the Golgi and trans-Golgi networks(TGNs) and formed additional dotted structures in the
cytoplasm (Figure 6B and Additional file 5: Figure S5).
The latter ones colocalized with neither endosomal and
lysosomal organelle markers nor Rab8a (Additional file 5:
Figure S5), indicating that they most likely represent
secretory vesicles independent of the endosomal recyc-
ling and basolateral sorting routes [44,45]. Plasmin
treatment triggered a remarkable expansion of vesicular
ILEI staining (Figure 6C), whereas the addition of apro-
tinin restricted ILEI to Golgi structures (Figure 6D).
This indicates that elevated ILEI secretion might be
linked to the accumulation of ILEI secretory vesicles
throughout the cytoplasm.
To see how these different subcellular ILEI localizations
would be discernible in tumor tissue, we performed
immunohistological analysis of overexpressed ILEI forms
in EpC40 tumors of non-treated and aprotinin-treated
mice (Figure 6 E to L). Aprotinin efficiently inhibited ILEI-
processing proteases in these tumors, implicating that se-
cretion was also affected. Consistently, aprotinin treatment
shifted large parts of the ILEI signal to strongly stained
granules in both WT and Δ-propeptide (ΔN-RS) ILEI–
overexpressing tumor cells (Figure 6G J). Cleavage-mutant
(FD) ILEI preferentially localized to dense granules inde-
pendently of aprotinin (Figure 6K and L).
In summary, these results suggest that the subcellular
localization of ILEI correlates with the secretory status
of the protein, with granular staining corresponding to
tubular Golgi and TGN structures and to low levels of
ILEI secretion, and with diffuse cytoplasmic staining
reflecting dispersed secretory vesicles and high ILEI se-
cretion levels.
Cytoplasmic ILEI localization strongly correlates with high
uPAR expression and poor prognosis in human breast
cancer
To explore the relevance of our findings in human can-
cer pathogenesis, we analyzed the extent to which ILEI
secretion, and thus subcellular localization of ILEI, cor-
related with tumor cell–associated uPAR protein expres-
sion in human breast tumor tissue samples. Accordingly,
immunohistochemistry for ILEI and uPAR was per-
formed on two human breast cancer arrays (Figure 7A).
Whereas tumors with granular ILEI localization showed
divergent uPAR levels, almost 90% of the carcinomas
with cytoplasmic ILEI localization showed high uPAR
expression (Figure 7B). These data reveal a tight correl-
ation between cytoplasmic ILEI localization and high
uPAR levels in human breast cancer and further confirm
that uPAR expression is an important prerequisite of
elevated ILEI secretion in tumor cells.
Both cytoplasmic ILEI localization and high tumor-cell
associated uPAR expression correlated significantly with
a shorter metastasis-free life span (Figure 7C, left and
Figure 6 Interleukin-like epithelial-to-mesenchymal transition inducer secretion levels correlate with altered subcellular localization of
the protein. (A) Western blot analysis of interleukin-like epithelial-to-mesenchymal transition inducer (ILEI) in whole-cell lysates and conditioned
medium (CM) of wild-type ILEI-overexpressing EpC40 cells (EpC40-wt) harvested 32 hours after serum withdrawal with or without treatment with
plasmin (10 mU/ml) for 8 hours before harvest or aprotinin (10 μM) for 32 hours before harvest. CM of the last 24 hours were collected. (B) to (D)
Immunofluorescence analysis of EpC40-wt cells as described in (A) without treatment (B) or after plasmin treatment (C) or aprotinin treatment
(D). ILEI is visualized via its FLAG tag (green), Golgi is marked by a GM130 antibody (red) and genomic DNA is counterstained with DAPI
(4′,6-diamidino-2-phenylindole, blue). Scale bar, 10 μm. (E) to (L) Immunohistochemistry for ILEI localization on representative 3-μm-thick sections
of paraffin-embedded EpC40 mammary tumors (n = 5 per group) overexpressing the empty vector control (cont.; (E) and (F)) or the following
ILEI constructs: EpC40-wt (G) and (H), EpC40-ΔN-RS (I) and (J) and EpC40-FD (K) and (L). (E, G, I and K) Tumors from nontreated animals.
(F, H, J and L) tumors from aprotinin-treated animals. Overexpressed ILEI is shown via its FLAG epitope tag (brown), and genomic DNA is
counterstained with hematoxylin (blue). Scale bar, 10 μm.
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Kaplan-Meier survival analysis of the two markers would
provide an enhanced prognostic power (Figure 7C, right
panel). In the combined analysis, the four categories dis-
tributed into clearly distinct survival frequencies (Figure 7C,
right panel). The combination “granular ILEI, low uPAR”
was able to identify patients with the best survival
chances. High uPAR expression indicated a moderately
but significantly decreased probability of survival of
patients with granular ILEI localization. Cytoplasmic ILEI
localization was almost exclusively coupled to high uPARexpression, thus the combined analysis gave survival fre-
quencies similar to those of cytoplasmic ILEI alone. Sur-
prisingly, the rare group “cytoplasmic ILEI, low uPAR”
showed the lowest frequency of survival. However, the low
incidence (6 of 88) and case number precluded conclusions
about the biological relevance of this group.
Breast cancer is a heterogeneous disease [48]. To test if
the prognostic effects of ILEI, uPAR and an ILEI-uPAR
combined analysis were applicable to all breast cancers,
ILEI and uPAR scores were correlated with the metasta-
sis-free survival of patients divided into the four major
Figure 7 Cytoplasmic interleukin-like epithelial-to-mesenchymal transition inducer localization correlates with high tumor-cell
associated urokinase plasminogen activator receptor expression, and a combined ILEI-uPAR marker analysis shows enhanced prognostic
power in human breast cancer. (A) Immunohistochemistry for interleukin-like epithelial-to-mesenchymal transition inducer (ILEI) localization
(granular or cytoplasmic, upper images) and urokinase plasminogen activator receptor (uPAR) expression (low or high, lower images) on
representative samples from two human breast cancer tissue arrays. ILEI/uPAR signal is in purple, and genomic DNA is in blue (counterstained
with hematoxylin and eosin). Scale bar, 50 μm. (B) Distribution of tumor-cell associated uPAR protein expression levels in 88 patients with
different subcellular ILEI localizations. (C) Evaluation of ILEI localization (left panel), tumor-cell associated uPAR expression (middle panel) and a
combined analysis of the two markers (right panel) for metastasis-free survival depicted in Kaplan-Meier plots.
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receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor 2 (HER2) expression
as luminal A (ER + and/or PR+, HER2−), luminal B (ER +
and/or PR+, HER2+), triple-negative (ER−, PR−, HER2−)
and HER2 type (ER−, PR−, HER2+) [49,50]. All four sub-
types were present in the cohort of the eighty-eight ana-
lyzed patients, and metastasis-free survival significantly
differed by subtype (Additional file 6: Figure S6A). Import-
antly, the ILEI, uPAR and combined categories distributed
into distinct survival frequencies within the luminal A,
triple-negative and HER2 subtypes (Additional file 6:
Figure S6B). In addition, the relative course of the sur-
vival frequencies of the four ILEI-uPAR categories in all
these subtypes was reminiscent of the bulk analysis of
all breast cancer patients (compare Figure 7C and
Additional file 6: Figure S6B, right panel). However,the low number of patients in each group precluded
making any statistically reliable conclusions about a po-
tentially enhanced prognostic power of these marker
analyses over cancer subtyping.
The four categories of ILEI and uPAR scores were cor-
related with established clinical and histopathological clas-
sifications of human breast cancer. As previously found
for ILEI localization [7], the combined ILEI-uPAR scores
maintained a significant correlation exclusively with the
HER2 status of tumors (Additional file 7: Table S1).
These analyses confirmed the strong independent
prognostic validity of ILEI localization for cancer survival.
Furthermore, they indicate a tight linkage of ILEI locali-
zation and tumor cell–associated uPAR expression, the
combined analysis of which might be beneficial in
prospectively identifying patients with the lowest, and
possibly the highest, risk of metastasis in breast cancer.
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We found plasmin, plasma kallikrein and NE to be able
to cleave ILEI at physiological concentrations. As part of
the blood coagulation–fibrinolytic system, both plasmin
and kallikrein are present in the blood at high levels.
The plasma concentration of NE is low in healthy condi-
tions, but it is highly elevated during chronic inflam-
mation, which is often linked to cancerous diseases [26].
Thus, as soon as tumor cells enter the circulation, the
secreted ILEI protein is most likely processed and active.
This is what our pulmonary metastasis studies indicate;
however, as our tumor formation experiments show, the
level of ILEI-processing proteases may be limited in the
primary tumor, suggesting that they may have a decisive
regulatory role at the site of tumor cell dissemination.
Plasmin, kallikrein and NE are potentially present in the
tumor stroma and could execute ILEI cleavage [14,26,51].
Plasma kallikrein could even play an enhancer function,
because it can also activate Plg, uPA and the release of NE
[52]. Hence, the relative abundance of these proteases
might set the final level of processed ILEI in the primary
tumor. The network of these proteases might also orches-
trate ILEI secretion. We found that plasmin is a key factor
in this process. Kallikrein is known to activate Plg and
uPAR signaling [22], and NE is able to cleave uPAR and
PAI-1 [53,54]. Hence, both proteases could thereby in-
fluence the net intensity of uPAR-mediated ILEI secre-
tion. In addition, plasmin, kallikreins and NE are
proteases with ECM-degrading activity [26,51] and thus
might also contribute to increased ILEI activity by ECM
degradation–driven release of the tethered protein. In
summary, all three enzymes are good candidates to have
important regulatory function on ILEI activity at multiple
levels, such as regulated secretion and release from the
ECM by direct proteolytic processing of the cytokine or
by ECM degradation.
Plasmin had a very robust effect on ILEI secretion. In
addition, active uPA was sufficient, and uPAR was essen-
tial, in the upregulation of ILEI secretion, suggesting a
Plg–uPA–uPAR axis of the regulatory mechanism. Yet,
there are numerous other ways that uPAR could be
activated [19], and additional targets of plasmin might
be relevant as well. The way in which uPAR increases
ILEI secretion remains unclear, too. Thus, the identifica-
tion of the relevant Plg–uPAR network and the uPAR
coreceptor will be critical in deciphering the mechanism
of uPAR-regulated ILEI secretion. In the present study, we
observed that elevated ILEI was secreted within 30 minutes
after plasmin treatment, suggesting that uPAR signaling
primarily acts on the ILEI secretory pathway, most probably
by regulating the budding of ILEI secretory vesicles from
the TGN.
We demonstrate that plasmin is involved in the pro-
teolytic cleavage of ILEI and is also responsible for theregulation of ILEI secretion. Thus, we expected protease
inhibitor treatment to affect both processes. However,
only cleavage-sensitive WT, and not Δ-propeptide ILEI,
showed decreased tumor growth and metastasis follow-
ing aprotinin treatment. Importantly, aprotinin inhibited
ILEI secretion, and secretion of Δ-propeptide ILEI and
ILEI-wt were similarly affected. This discrepancy can be
explained by the fact that induction of ILEI secretion
required lower plasmin levels than proteolytic cleavage.
Thus, residual protease activity after aprotinin treatment
might have been sufficient to maintain reasonable levels
of ILEI secretion, but secreted ILEI-wt most probably
remained unprocessed and inactive, whereas Δ-propeptide
ILEI could function. These studies show that aprotinin-
sensitive proteolytic processing plays an essential role in
ILEI function and that plasmin-induced ILEI secretion is
independent of this process. Nevertheless, overexpressed
Δ-propeptide, WT and cleavage-mutant forms of ILEI
showed differences in their secretion capacities that cor-
related with their localization patterns and activities.
Although we could not detect differences in the expres-
sion levels of important components of the Plg–uPAR
system in overexpressing cells, it is possible that autocrine
signaling is involved in the feedback regulation of ILEI
secretion.
In contrast to earlier findings, however, no evidence
for an autocrine ILEI signaling was found during our
in vitro analyses of the activity of the different ILEI mu-
tants. We also found no differences in the anchorage-
independent growth or in assays to address the role of
EMT in vitro (three-dimensional cell culture assay and
analysis of EMT markers) in the tumor cells overexpress-
ing different ILEI forms compared to their controls (data
not shown). Very importantly, and as a major difference
from the earlier studies on ILEI, however, all experiments
were performed with cell pools in our study. Thus, we did
not perform any clonal selection of cells in vitro after
introducing the different ILEI constructs; instead, clonal
selection took place in vivo in the tumors. By this process,
differences in the activity of the different ILEI forms
might have been masked in vitro within the cell pools,
but could be efficiently demonstrated in vivo in the cor-
relative tumor formation and metastasis assays.
Our human breast cancer tissue array analysis showed
an enhanced prognostic value of a combined ILEI-uPAR
analysis. Granular ILEI localization coupled with high
uPAR expression levels predicted somewhat lower survival
frequencies than the combination of granular ILEI-low
uPAR. A low ILEI secretion level despite high uPAR ex-
pression indicates other important components of uPAR
signaling/ILEI secretory machinery missing in those
tumors. Hence, a worse prognosis might be due to
other known invasion- and metastasis-promoting actions
of uPAR. Cytoplasmic ILEI was associated with poor
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almost 90% of the cases. The few cases showing cytoplas-
mic ILEI despite low uPAR levels, however, unexpectedly
had the worst survival prognosis. Only an extended ana-
lysis of tumor samples will be able to answer the biological
relevance of this group. Further experiments on a larger
data set will be needed to show how other prognostic
markers of the uPAR system (for example, uPA and PAI-1
[47,55]) correlate with ILEI localization and whether high
expression of these markers could compensate for low
uPAR levels. The prognostic value of ILEI localization and
of a combined ILEI-uPAR analysis was potentially relevant
for all four major breast cancer subtypes that were investi-
gated in this study. However, the low number of patients
included is a clear limitation of the study, and a larger
number of cases will be required for an accurate statistical
analysis in the future. It will be also be interesting to see
how the prognostic value of a combined ILEI-uPAR
analysis correlates with other subtyping biomarkers that
were not included in our present study, such as the basal
markers epidermal growth factor receptor and cytokeratin
5/6 of triple-negative tumors.
Conclusions
Our results suggest that plasmin plays a pivotal role in
the regulation of ILEI processing and secretion and that
uPAR-regulated ILEI secretion levels are decisive in
tumor progression. They also indicate that the Plg-uPAR
system may serve as a potential therapeutic target and
an important prognostic factor in ILEI-dependent breast
tumor progression.
Additional files
Additional file 1: Figure S1. Loss of Plg partially impairs ILEI-processing
capacity of serum and plasma, and mutation of the proteolytic cleavage
site in ILEI prevents processing by plasmin. (A) Purified full-length
ILEI-6xHis was incubated with medium containing 10% FCS (DMEM 10%)
or CM of EpRas cells (EpRas CM) or added directly to the culture of EpRas
cells (EpRas co-inc.) for 24 hours. ILEI protein was repurified via its
6xHis affinity tag and evaluated by Western blot analysis. (B) Western
blot analysis of ILEI in CM of EpRas cells grown in the presence of 10%
complete or Plg-depleted FCS. Loading was normalized to cell numbers.
(C) Analysis of murine blood plasma for ILEI-processing capacity. Western
blot analysis of purified full-length ILEI incubated with blood plasma of
Plg-KO mice and their wild-type (wt) or heterozygous littermates. Each
lane contains a plasma sample of a separate mouse. (D) In vitro plasmin
cleavage assay of ILEI cleavage mutants. WT and cleavage-mutant (FD
and DF) ILEI proteins purified via their FLAG epitope tag from lysates of
overexpressing EpRas cells were incubated with purified plasmin for
24 hours and subjected to Western blot analysis.
Additional file 2: Figure S2. ILEI and its processing are essential for
metastasis formation of murine 4T1 mammary cancer cells. (A) ILEI
Western blot analysis of whole-cell lysates and CM of parental 4T1 cells,
control (shCont) and ILEI KD (shILEI) 4T1 cells and ILEI KD 4T1 cells
reconstituted with wild-type (wtrescue), cleavage-mutant (FDrescue) and
Δ-propeptide (ΔN-RSrescue) ILEI constructs. The last lane of the CM blot
was inserted from a separate part of the same gel. (B) Tumor masses ±
SEM 30 days after injection of 4T1 cells and derivatives into themammary gland fat pads of female nude mice (n = 6 to 10 per group).
(C) Histological analysis of lung metastases of mice that received injections
into the fat pad. Scale bar, 2 mm. (D) The percentage of lung metastatic
area ± SEM for each group.
Additional file 3: Figure S3. Induction of ILEI secretion by plasmin,
TGFβ and uPA and efficient uPAR KD by stable RNAi in EpRas cells. (A)
Western blot analysis of ILEI in whole-cell lysates and CM of EpRas cells
not treated or treated with purified plasmin of the indicated concentrations
for 24 hours after serum withdrawal. (B) Western blot analysis of ILEI in
whole-cell lysates and CM of EpRas cells without treatment or following
TGFβ-1 (10 ng/ml), plasmin (10 mU/ml) or a combined treatment for
16 hours after serum withdrawal or reduction to 4%. (C) Western blot
analysis of ILEI in whole-cell lysates and CM of EpRas cells harvested 24 hours
after serum withdrawal and incubated with recombinant TGFβ-1 (10 ng/ml)
or purified plasmin (10 mU/ml) for the indicated periods of time before
harvest. (D) Western blot analysis of ILEI in whole-cell lysates and CM of
EpRas cells not treated or treated with purified active uPA of the indicated
concentrations for 24 hours after serum withdrawal. (E) Relative uPAR
mRNA expression of EpRas cells stably expressing nontargeting (shCont) or
uPAR-targeting shRNAs (sh_uPAR 1 to 5) determined by quantitative RT-PCR
and normalized to GAPDH mRNA levels. Error bars show standard deviations
of triplicates.
Additional file 4: Figure S4. Expression of components of the
Plg-uPAR system correlates with the extent and plasmin-dependent
inducibility of ILEI secretion in human breast cancer cell lines. (A) ILEI
expression and secretion levels shown by Western blot analysis of
whole-cell lysates and CM of MCF7, T47D, MDA-MB-468, MDA-MB-231
and CAMA1 cells. Last two lanes of each blot were inserted from a
separate part of the same gel. (B) Relative uPAR, uPA, tPA, PAI-1 and
PAI-2 mRNA expression levels of MCF7, T47D, MDA-MB-468, MDA-MB-231
and CAMA1 cells determined by quantitative RT-PCR and normalized to
GAPDH mRNA levels. Error bars indicate mean ± SEM of three independent
experiments. (C) Western blot analysis of ILEI expression and secretion levels
of whole-cell lysates and CM of MCF7 and MDA-MB-231 cells cultured in 4%
FCS containing medium for 24 hours in the absence or presence of plasmin
(10 mU/ml).
Additional file 5: Figure S5. ILEI primarily colocalizes with Golgi and
trans-Golgi network secretory organelles, but not with endosomal or
degradatory compartments. Immunofluorescence analysis of subcellular
ILEI localization in EpC40-wt (left panel), EpC40-ΔN-RS (middle panel)
and EpC40-FD (right panel) cells. ILEI (green) was detected by using an
ILEI-specific antibody. Markers of different cellular compartments (red) are
visualized by specific antibodies (giantin, TGN38, EEA1 and Lamp1) or by
autofluorescence following transient delivery of a fluorochrome-coupled
protein (transferrin) or transient expression of an mCherry fusion protein
(Rab8a). Genomic DNA (blue) is counterstained with DAPI. Scale bar,
10 μm.
Additional file 6: Figure S6. Analysis of the prognostic power of ILEI,
uPAR and a combined marker analysis in human breast cancer subtypes.
(A) Kaplan-Meier plots depicting metastasis-free survival of patients
evaluated for the four major breast cancer subtypes. (B) Kaplan-Meier
plots depicting metastasis-free survival of patients of each breast cancer
subtype evaluated for ILEI localization (left panels), tumor cell–associated
uPAR expression (middle panels) and a combined analysis of the two
markers (right panels).
Additional file 7: Table S1. Correlation of ILEI and uPAR IHC status
with established clinical and histopathological parameters of human
breast cancer.Abbreviations
CM: Conditioned medium; ECM: Extracellular matrix; EMT: Epithelial-to-
mesenchymal transition; ER: Estrogen receptor; HER2: Human epidermal
growth factor receptor 2; ILEI: Interleukin-like epithelial-to-mesenchymal
transition inducer; KD: Knockdown; NE: Neutrophil elastase; PAI: Plasminogen
activator inhibitor; Plg: Plasminogen; PR: Progesterone receptor; RNAi: RNA
interference; shRNA: Short-hairpin RNA; TGN: Trans-Golgi network; tPA: Tissue
plasminogen activator; uPA: Urokinase plasminogen activator;
uPAR: Urokinase plasminogen activator receptor.
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